ClinicalTrials.gg
Not yet recruitingNCT06653959Updated Oct 23, 2024

Precision Transcranial Magnetic Stimulation for Patients With Post-stress Sleep Disorders

An interventional study of active Transcranial Magnetic Stimulation and sham Transcranial Magnetic Stimulation in Stress, Psychological, Sleep Initiation and Maintenance Disorders and Transcranial Magnetic Stimulation, sponsored by Xijing Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-10-23.

Sponsored by Xijing Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Stress, Psychological with a site in China — 9 open to participants now, 11 under way, none of them phase 3. Stress, Psychological · China.

Planned enrollment
17th of 19
60 · median 126
Started
2024
with 5 others
No phase
18 of 28
4 open now
Primary completion
2025-12
later than 5 of 10 live
Registered
17th of 28
by date

Among the 28 studies in Stress, Psychological with a site in China, this one is the 17th largest by planned enrollment of the 19 interventional ones that give a count, is one of 6 that started in 2024, is one of 18 with no phase, reaches primary completion later than 5 of the 10 other live ones, and was the 17th registered.

Stress, Psychological

853 studies on the registry are indexed under Stress, Psychological; 141 are open to participants now.

Browse Stress, Psychological studies →

Open to participants now

9 of the 28 studies in Stress, Psychological with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 74 Stress, Psychological studies recruiting now, 34 (46%) set no upper age limit and 36 (49%) stop at 75 or younger; 13 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Stress, Psychological with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind controlled study that recruited patients with insomnia problems after suffering a stressful event to undergo individualized transcranial magnetic stimulation

Read the detailed description

This is a randomized, double-blind controlled study that will recruit patients who have experienced a stressful event and currently exhibit severe sleep problems for transcranial magnetic stimulation. They will be randomly assigned to the trial and control groups and will receive 5 consecutive days of continuous theta-wave stimulation, and before and after the treatment they will be assessed on clinical scales and undergo magnetic resonance examinations as well as sleep monitoring.

03

Conditions studied

  • Stress, Psychological
  • Sleep Initiation and Maintenance Disorders
  • Transcranial Magnetic Stimulation
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be between the ages of 18 and 60 (both 18 and 60) and of any gender;
  2. Experienced a severe traumatic event;
  3. Stanford Acute Stress Reaction Questionnaire (SASRQ) ≥40 points;
  4. PSQI > 7 points;
  5. Good compliance and willingness to undergo this therapy.

Exclusion criteria

Exclusion Criteria:

  1. Sleep disorders that can be explained by a primary illness;
  2. Concurrent psychotherapy;
  3. Those with to magnetic resonance examination and transcranial magnetic stimulation therapy;
  4. Combined with serious cardiovascular, hepatic, renal, digestive, hematopoietic system and other primary diseases.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    active Transcranial Magnetic Stimulation

    The most relevant site of functional connectivity between vlPFC-VTA will be targeted for continuous theta burst stimulation

    Device: active Transcranial Magnetic Stimulation

  • Placebo comparator
    sham Transcranial Magnetic Stimulation

    The most relevant site of functional connectivity between vlPFC-VTA will be targeted for sham continuous theta burst stimulation

    Device: sham Transcranial Magnetic Stimulation

Interventions

  • Deviceactive Transcranial Magnetic Stimulation

    Based on each individual's MRI data, individualized stimulation targets will be found, and then this will be used for stimulation for 5 consecutive days.

  • Devicesham Transcranial Magnetic Stimulation

    Based on each individual's MRI data, individualized stimulation targets will be found, and then this will be used for sham stimulation for 5 consecutive days.

06

What researchers measure

Primary outcomes

  1. Change in Pittsburgh sleep quality index (PSQI) scores from baseline to post-treatment

    The Pittsburgh Sleep Quality Index, compiled in 1989 by Dr. Buysse, a psychiatrist at the University of Pittsburgh, and others. It is suitable for patients with sleep disorders to evaluate the quality of their sleep, as well as for the general population to assess the quality of their sleep. The scale consists of 9 questions, of which the first 4 are fill-in-the-blanks and the last 5 are multiple-choice (question 5 contains 10 sub-questions) Change = (treatment day 5 Score -Baseline Score).

    Time frame: Baseline and treatment day 5

Secondary outcomes

  1. Change in Posttraumatic Stress Disorder Check List for Diagnostic and Statistical Manual of Mental Disorders-5 scores from baseline to treatment day 5

    Posttraumatic Stress Disorder Check List for Diagnostic and Statistical Manual of Mental Disorders-5(PCL-5) is a validated, self-reported instrument assessing PTSD symptom severity over the past week or month period .Possible scores range from 0 to 80 . Change = (treatment day 5 Score -Baseline Score).

    Time frame: Baseline and treatment day 5

  2. Change in Stanford Acute Stress Reaction Questionnaire (SASRQ) scores from baseline to treatment day 5

    The Stanford Acute Stress Reaction Questionnaire (SASRQ) is a commonly used international instrument for assessing acute stress disorders. It consists of 5 dimensions, including alertness, dissociation, avoidance, re-experiencing, and impairment of social functioning, with a total of 30 items, ranging from "not experiencing" to "always experiencing". A total of 30 items, ranging from "no experience" to "always experience", were assigned a score of 0 to 5, with a total score of 0 to 150. The higher the total score, the more severe the acute stress disorder, with a score of ≥40 suggesting a moderate likelihood of acute stress disorder. Change = (treatment day 5 Score -Baseline Score).

    Time frame: Baseline and treatment day 5

  3. Change in Hamilton Depression Scale(HAMD-17)scores from baseline to treatment day 5 Score

    Hamilton Depression Scale(HAMD-17) is a commonly used clinical evaluation standard for the severity of depressive symptoms. There are 17 items in total, which can be scored before and after treatment to evaluate the severity of the disease and the treatment effect.Possible scores range from 0 to 52 and the higher the score, the worse the symptom. Change = (treatment day 5 Score -Baseline Score).

    Time frame: Baseline and treatment day 5

  4. Change in Hamilton Anxiety Scale scores from baseline to treatment day 5 Score

    Hamilton Anxiety Scale (HAMA)is suitable for assessing the severity of anxiety symptoms. It has 14 items and adopts a 5-level scoring method of 0-4 points.Possible scores range from 0 to 56 and the higher the score, the worse the symptom. Change = (treatment day 5 Score -Baseline Score).

    Time frame: Baseline and treatment day 5

  5. Change in Posttraumatic Stress Disorder Check List for Diagnostic and Statistical Manual of Mental Disorders-5 scores from baseline to 28 days after the end of treatment

    Posttraumatic Stress Disorder Check List for Diagnostic and Statistical Manual of Mental Disorders-5(PCL-5) is a validated, self-reported instrument assessing PTSD symptom severity over the past week or month period .Possible scores range from 0 to 80 . Change = (28 days after the end of treatment Score -Baseline Score).

    Time frame: Baseline and 28 days after the end of treatment

  6. Change in Stanford Acute Stress Reaction Questionnaire (SASRQ) scores from baseline to 28 days after the end of treatment

    The Stanford Acute Stress Reaction Questionnaire (SASRQ) is a commonly used international instrument for assessing acute stress disorders. It consists of 5 dimensions, including alertness, dissociation, avoidance, re-experiencing, and impairment of social functioning, with a total of 30 items, ranging from "not experiencing" to "always experiencing". A total of 30 items, ranging from "no experience" to "always experience", were assigned a score of 0 to 5, with a total score of 0 to 150. The higher the total score, the more severe the acute stress disorder, with a score of ≥40 suggesting a moderate likelihood of acute stress disorder. Change = (28 days after the end of treatment Score -Baseline Score).

    Time frame: Baseline and 28 days after the end of treatment

  7. Change in Hamilton Depression Scale(HAMD-17)scores from baseline to 28 days after the end of treatment

    Hamilton Depression Scale(HAMD-17) is a commonly used clinical evaluation standard for the severity of depressive symptoms. There are 17 items in total, which can be scored before and after treatment to evaluate the severity of the disease and the treatment effect.Possible scores range from 0 to 52 and the higher the score, the worse the symptom. Change = (28 days after the end of treatment Score -Baseline Score).

    Time frame: Baseline and 28 days after the end of treatment

  8. Change in Hamilton Anxiety Scale scores from baseline to 28 days after the end of treatment

    Hamilton Anxiety Scale (HAMA)is suitable for assessing the severity of anxiety symptoms. It has 14 items and adopts a 5-level scoring method of 0-4 points.Possible scores range from 0 to 56 and the higher the score, the worse the symptom.

    Time frame: Baseline and 28 days after the end of treatment

07

Study locations

1 site
08

References and documents

Publications

  • Cai M, Zhu Y, Shanley MR, Morel C, Ku SM, Zhang H, Shen Y, Friedman AK, Han MH. HCN channel inhibitor induces ketamine-like rapid and sustained antidepressant effects in chronic social defeat stress model. Neurobiol Stress. 2023 Aug 19;26:100565. doi: 10.1016/j.ynstr.2023.100565. eCollection 2023 Sep. PubMed 37664876 ↗
  • Luo YJ, Li YD, Wang L, Yang SR, Yuan XS, Wang J, Cherasse Y, Lazarus M, Chen JF, Qu WM, Huang ZL. Nucleus accumbens controls wakefulness by a subpopulation of neurons expressing dopamine D1 receptors. Nat Commun. 2018 Apr 20;9(1):1576. doi: 10.1038/s41467-018-03889-3. PubMed 29679009 ↗
  • Brunelin J, Jalenques I, Trojak B, Attal J, Szekely D, Gay A, Januel D, Haffen E, Schott-Pethelaz AM, Brault C; STEP Group; Poulet E. The efficacy and safety of low frequency repetitive transcranial magnetic stimulation for treatment-resistant depression: the results from a large multicenter French RCT. Brain Stimul. 2014 Nov-Dec;7(6):855-63. doi: 10.1016/j.brs.2014.07.040. Epub 2014 Aug 7. PubMed 25192980 ↗
  • Blumberger DM, Maller JJ, Thomson L, Mulsant BH, Rajji TK, Maher M, Brown PE, Downar J, Vila-Rodriguez F, Fitzgerald PB, Daskalakis ZJ. Unilateral and bilateral MRI-targeted repetitive transcranial magnetic stimulation for treatment-resistant depression: a randomized controlled study. J Psychiatry Neurosci. 2016 Jun;41(4):E58-66. doi: 10.1503/jpn.150265. PubMed 27269205 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2024; primary completion for Dec 2025, 13 months later.

Of 462 non-industry interventional studies with no phase under Stress, Psychological, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 13 months is close to that.

Counting every sponsor, half of 475 studies reached it within 13 months; a quarter within 5 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 23, 2024
StartEst.
Nov 1, 2024
Primary completionEst.
Dec 1, 2025
CompletionEst.
Dec 31, 2025
Last update
Oct 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06653959
Lead sponsor
Xijing Hospital
Responsible party
Sponsor
First posted
Oct 23, 2024
Start date
Nov 1, 2024 (estimated)
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Oct 23, 2024

Study contacts

yaochi Zhang
Contact
a18294037117@163.com
18294037117
Min Cai, PhD
principal investigator · Xijing Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion